Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis

Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 studies. Treating HCV genotype (GT) 3 infection remains a priority, as these patients are harder to cure and at a greater risk for liver steatosis, fibr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Viral Hepat
Main Authors: Flamm, Steven, Mutimer, David, Asatryan, Armen, Wang, Stanley, Rockstroh, Jürgen, Horsmans, Yves, Kwo, Paul Y., Weiland, Ola, Villa, Erica, Heo, Jeong, Gane, Edward, Ryder, Stephen D., Welzel, Tania M., Ruane, Peter J., Agarwal, Kosh, Ng, Teresa I., Xue, Zhenyi, Lovell, Sandra S., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Trinh, Roger, Mensa, Federico J., Wyles, David L.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7379735/
https://ncbi.nlm.nih.gov/pubmed/30421537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvh.13038
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados